These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 4200486)
1. A new antitumor antimetabolite, (alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): antimicrobial reversal studies and preliminary evaluation against L1210 mouse leukemia in vivo. Hanka LJ; Martin DG; Neil GL Cancer Chemother Rep; 1973 Apr; 57(2):141-8. PubMed ID: 4200486 [No Abstract] [Full Text] [Related]
2. A new antitumor agent, (alphas, 4s, 5r)-alpha-amino-3-chloro-4-hydroxy-4,5-dihydro-5-isoxazoleacetic acid (NSC-176324): preliminary evaluation against L 1210 mouse leukemia in vivo. Martin DG; Hanka LJ; Neil GL Cancer Chemother Rep; 1974; 58(6):935-7. PubMed ID: 4217217 [No Abstract] [Full Text] [Related]
3. Biochemical and pharmacological effects of the fermentation-derived antitumor agent, (alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125). Neil GL; Berger AE; McPartland RP; Grindey GB; Bloch A Cancer Res; 1979 Mar; 39(3):852-6. PubMed ID: 427775 [No Abstract] [Full Text] [Related]
4. Enhanced effect of an L-glutamine antagonist, L-(alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, by Acinetobacter L-glutaminase-L-asparaginase. Holcenberg JS Cancer Treat Rep; 1979 Jun; 63(6):1109-14. PubMed ID: 466650 [TBL] [Abstract][Full Text] [Related]
5. Studies of the biochemical pharmacology of the fermentation-derived antitumor agent, (alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125). Neil GL; Berger AE; Bhuyan BK; Blowers CL; Kuentzel SL Adv Enzyme Regul; 1978; 17():375-98. PubMed ID: 757314 [No Abstract] [Full Text] [Related]
6. L-[alphaS, 5S]-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): a new amino acid antibiotic with the properties of an antagonist of L-glutamine. Jayaram HN; Cooney DA; Ryan JA; Neil G; Dion RL; Bono VH Cancer Chemother Rep; 1975; 59(3):481-91. PubMed ID: 1147 [TBL] [Abstract][Full Text] [Related]
7. Mechanism of resistance of a variant of P388 leukemia to L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin). Jayaram HN; Ardalan B; Deas M; Johnson RK Cancer Res; 1985 Jan; 45(1):207-12. PubMed ID: 2578092 [TBL] [Abstract][Full Text] [Related]
8. Therapy for mouse tumors and human tumor xenografts with the antitumor antibiotic AT-125. Houchens DP; Ovejera AA; Sheridan MA; Johnson RK; Bogden AE; Neil GL Cancer Treat Rep; 1979 Mar; 63(3):473-6. PubMed ID: 427827 [TBL] [Abstract][Full Text] [Related]
9. Experimental antitumor activity and toxicity of a new chemotherapeutic agent, BBM 928A. Rose WC; Schurig JE; Huftalen JB; Bradner WT Cancer Res; 1983 Apr; 43(4):1504-10. PubMed ID: 6831399 [No Abstract] [Full Text] [Related]
10. Activity of anthracyclines against an adriamycin (NSC-123127)-resistant subline of P388 leukemia with special emphasis on cinerubin A (NSC-18334). Johnson RK; Ovejera AA; Goldin A Cancer Treat Rep; 1976 Jan; 60(1):99-102. PubMed ID: 826316 [No Abstract] [Full Text] [Related]
11. Evaluation of the antitumor activity of rifamycin SV. Adamson RH Arch Int Pharmacodyn Ther; 1971 Jul; 192(1):61-5. PubMed ID: 5093193 [No Abstract] [Full Text] [Related]
12. Chemotherapeutic effects of compound 593A (NSC-135758) on mouse leukemias and some transplanted animal tumors. Tarnowski GS; Schmid FA; Hutchison DJ; Stock CC Cancer Chemother Rep; 1973 Feb; 57(1):21-7. PubMed ID: 4704098 [No Abstract] [Full Text] [Related]
13. Studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-,dihydrochloride. III. Biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with melphalan, cyclophosphamide, and BCNU. Schabel FM; Trader MW; Laster WR; Shaddix SC; Brockman RW Cancer Treat Rep; 1976 Sep; 60(9):1325-33. PubMed ID: 1016968 [TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of macromomycin B (NSC 170105) against murine leukemias, melanoma, and lung carcinoma. Lippman MM; Laster WR; Abbott BJ; Venditti J; Baratta M Cancer Res; 1975 Apr; 35(4):939-45. PubMed ID: 1116151 [TBL] [Abstract][Full Text] [Related]
15. Studies on the antitumor activity of an alazopeptin isolated from a new strain of Streptomyces. Hata T; Umezawa I; Iwai Y; Katagiri M; Awaya J J Antibiot (Tokyo); 1973 Mar; 26(3):181-3. PubMed ID: 4205875 [No Abstract] [Full Text] [Related]
16. Antitumor activity of pyrazofurin in combination with 5-azacytidine against murine P388 and L1210 leukemias and colon carcinoma 26. Chiuten DF; Muggia FM; Johnson RK Cancer Treat Rep; 1979; 63(11-12):1857-62. PubMed ID: 93512 [No Abstract] [Full Text] [Related]
18. The inhibition of gamma-glutamyl transpeptidase from human pancreatic carcinoma cells by (alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125; NSC-163501). Allen L; Meck R; Yunis A Res Commun Chem Pathol Pharmacol; 1980 Jan; 27(1):175-82. PubMed ID: 6102405 [TBL] [Abstract][Full Text] [Related]
19. Antitumor activity and preliminary drug disposition studies on chartreusin (NSC 5159). McGovren JP; Neil GL; Crampton SL; Robinson MI; Douros JD Cancer Res; 1977 Jun; 37(6):1666-72. PubMed ID: 870180 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the antileukemic effect in mice of adriamycin (NSC-123127) with daunomycin (NSC-82151). Sandberg JS; Howsden FL; DiMarco A; Goldin A Cancer Chemother Rep; 1970 Feb; 54(1):1-7. PubMed ID: 5527012 [No Abstract] [Full Text] [Related] [Next] [New Search]